DEF: Invivyd Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Invivyd, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on May 20, 2025, featuring proposals for director elections and ratification of the company's independent accounting firm.

Summary

• Invivyd, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on May 20, 2025, at 8:30 a.m. Eastern Time.
• Stockholders of record as of March 21, 2025, are eligible to vote.
• The meeting will address the election of six director nominees for a one-year term expiring at the 2026 Annual Meeting.
• It will also include the ratification of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board of Directors recommends voting FOR ALL director nominees and FOR the ratification of PricewaterhouseCoopers LLP.
• The company had 119,961,445 shares of common stock outstanding and entitled to vote as of the record date.
• The Board size will be decreased from seven to six directors effective as of the 2025 Annual Meeting.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral tone. The company is following standard corporate governance practices, which is generally viewed positively.

Positives

• The company is providing a virtual meeting format to increase accessibility for stockholders worldwide.
• The Board is recommending experienced and independent director nominees for election.
• The Audit Committee has pre-approved all audit and non-audit services provided by PricewaterhouseCoopers LLP.
• The company has a clawback policy in place to recover incentive compensation from executive officers in the event of certain accounting restatements.
• The company has adopted an insider trading prevention policy and a hedging policy to promote compliance with securities laws.

Negatives

• Current director Srishti Gupta, M.D. is not standing for re-election at the 2025 Annual Meeting, reducing the board size from seven to six.
• Former executives David Hering and Jeremy Gowler departed from the company in 2024, requiring separation agreements and payments.

Risks

• Failure to ratify the appointment of PricewaterhouseCoopers LLP could require the Audit Committee to reconsider its choice of accounting firm.
• The company's success depends on retaining qualified personnel, including executive officers and directors.
• Related person transactions, such as agreements with Adimab and PHP, could present potential conflicts of interest.
• The company's reliance on third-party relationships, such as those with Adimab, could impact its ability to develop and commercialize products.

Future Outlook

The document does not contain specific forward-looking financial statements, but it outlines the company's plans for director elections and auditor ratification, which are essential for future governance and financial oversight.

Management Comments

• Our Board recommends that stockholders vote FOR ALL for Proposal No. 1 and FOR Proposal No. 2.
• It is important that your shares be represented at the Annual Meeting regardless of the size of your holdings.

Industry Context

This announcement is typical for publicly traded companies as they prepare for their annual meetings, ensuring compliance with SEC regulations and providing stockholders with the opportunity to participate in key decisions.

Comparison to Industry Standards

• The virtual meeting format aligns with a growing trend among public companies to enhance accessibility and reduce costs.
• The director compensation structure and equity incentive plans are consistent with industry practices for attracting and retaining qualified board members.
• The related person transaction disclosures are in line with SEC requirements and provide transparency to stockholders.
• The company's corporate governance policies, such as the clawback policy and insider trading prevention policy, reflect best practices for risk management and compliance.

Management Changes

Corporate Governance

Related Party Transactions

• The company has agreements with Adimab, a significant stockholder, for antibody discovery and optimization.
• The company had a Master Services Agreement with PHP, where a former and current board member are partners.

Stakeholder Impact

• Stockholders have the opportunity to vote on key governance matters.
• Employees are affected by executive compensation policies and equity incentive plans.
• The company's relationships with suppliers and partners, such as Adimab, are important for its operations.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on May 20, 2025.
• The company will announce the voting results in a Current Report on Form 8-K within four business days of the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Director Election, PricewaterhouseCoopers, Corporate Governance, Stockholders, Invivyd, Board of Directors